Reporting adverse event or adverse drug reaction

Reporting adverse event or adverse drug reaction
The following information, appearing in Polish, refers to the reporting adverse event of adverse drug reaction only on territory of Poland. For more information in English please contact us: +48 22 56 62 630

Komtur Polska Sp. z o.o. makes a kind request to report all information on suspected adverse event or adverse drug reaction after the following medicinal products:

Marketing Authorisation Holder: Riemser Pharma GmbH:

  • Aldactone (Kalii canrenoas) 20 mg/ml, solution for injection

Marketing Authorisation Holder: Cheplapharm Arzneimittel GmbH:

  • Cymevene (Ganciclovirum) 500 mg, powder for solution for injection
  • Dilatrend (Carvedilolum) 6,25 mg; 12 mg; 25 mg; tablets
  • Ditropan (Oxybutyninum) 5 mg, tablets
  • Dormicum (Midazolamum) 7,5 mg; 15 mg, film-coated tablets
  • Fungizone (Amphotericinum B) 50 mg, powder for solution for injection
  • Heminevrin (Clomethiazolum) 300 mg, capsules hard
  • Inhibace (Cilazaprilum) 1 mg; 2,5 mg; 5 mg; film-coated tablets
  • Inhibace Plus (Cilazaprilum + Hydrochlorothiazidum) 5 mg + 12,5 mg; film-coated tablets
  • Lexotan (Bromazepamum) 3 mg; 6 mg, tablets
  • Vesanoid (Tretinoinum) 10 mg, capsules soft
  • Visudyne (Verteporfinum) 15 mg, powder for solution for infusion
  • Xenical (Orlistatum) 120 mg, capsules hard


Marketing Authorisation Holder: Atnahs Pharma UK Ltd

  • Bonviva (Acidum ibandronicum) 3 mg/ 3 ml, solution for injection
  • Bonviva (Acidum ibandronicum) 150 mg, film-coated tablets